Global Neurodegenerative Disease Market to Record a CAGR of 7.4% During 2019-2026 - Breakdown by Drug, Indication & Geography -

DUBLIN--()--The "Global Neurodegenerative Disease Market Analysis 2019" report has been added to's offering.

The Global Neurodegenerative Disease market is poised to grow at a CAGR of 7.4% during the forecast period.

Growing prevalence of neurological disorders, increasing public awareness, and strong product pipeline for neurodegenerative disease treatment are some of the factors driving the market growth. However, lack of awareness among the people in the under-developed regions and the absence of the developed curative treatment are hampering the growth of the market.

Based on the indication type, the Parkinson's disease segment is estimated to have a lucrative growth during the forecast period due to the disease is a slowly progressive neurologic disease that is characterized by a fixed inexpressive face, tremor at rest, slowing of voluntary movements, gait with short accelerating steps, peculiar posture and muscle weakness and low production of the neurotransmitter dopamine. The treatment involves the use of medication, such as levodopa and carbidopa.

The key vendors mentioned are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical, and UCB S.A.

Key Questions Answered in this Report

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Neurodegenerative Disease Market, By Drug Type

5.1 Introduction

5.2 Selective Serotonin Reuptake Inhibitor

5.4 Dopamine Inhibitors

5.5 N-methyl-D-aspartate Receptor

5.6 Other Drug Types

6 Global Neurodegenerative Disease Market, By Indication Type

6.1 Introduction

6.2 Huntington Disease

6.3 Parkinson's Disease

6.4 Spinal Muscular Atrophy

6.5 Alzheimer's Disease

6.6 Amyotrophic Lateral Sclerosis

6.7 Other Indication Types

7 Global Neurodegenerative Disease Market, By Geography

7.1 Introduction

7.2 North America

7.3 Europe

7.4 Asia-Pacific

7.5 South America

7.6 Middle East & Africa

8 Strategic Benchmarking

9 Vendors Landscape

9.1 AbbVie Inc.

9.2 Amneal Pharmaceuticals Inc.

9.3 Boehringer Ingelheim International GmbH

9.4 Hoffmann-La Roche Ltd.

9.5 GlaxoSmithKline PLC

9.6 Merck & Co. Inc.

9.7 Pfizer Inc.

9.8 Teva Pharmaceutical

9.9 UCB S.A.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900